Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis
Veradermics has reported strong Phase 2/3 results for its hair loss treatment VDPHL01, demonstrating significant hair regrowth compared to placebo with a favorable safety profile. The drug, an oral extended-release minoxidil, is positioned to address a large, underserved market for hair loss therapies. These results support the company's late-stage pipeline and commercial potential in the dermatology space.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895248-veradermics-positive-vdphl01-data-strengthens-late-stage-pipeline-thesis"},"author":{"@type":"Person","name":"Petri Dish…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
